5 years ago

Neurovalens Secures €5.5 Million to Expand High-Tech Headset for Neurological Conditions

  • Neurovalens, a healthtech startup based in Belfast and San Diego, has raised €5.5 million in a Series A funding round led by IQ Capital

  • The funding will be used to develop the company's technology, which uses non-invasive methods to influence the brainstem and hypothalamus to treat neurological diseases, for other conditions such as diabetes, obesity, anxiety, and insomnia

  • The company is currently in the final phase of trials for obesity and aims to have approval for insomnia and anxiety devices within the next 12 months, with diabetes trials planned for 2021.

      • ProblemHealthcare

      "Millions of people suffer from neurological and metabolic diseases like diabetes, obesity, anxiety and insomnia, significantly impacting their quality of life and placing a burden on healthcare systems."

      Solution

      "Neurovalens offers a non-invasive, high-tech headset that uses neurostimulation to influence the brainstem and hypothalamus, potentially treating these conditions without the need for implanted electrodes or medication."

      Covered on